Dublin, Aug. 19, 2020 (GLOBE NEWSWIRE) -- The "High Energy Chemistry/Hazardous Chemistry-based API Manufacturing Services Market: Focus on High Temperature, Low Temperature/Cryogenic, High Pressure and Low Pressure Chemistries, 2020-2030" report has been added to ResearchAndMarkets.com's offering.

The report features an extensive study on the current landscape and the likely future potential of the companies offering services for API manufacturing based on high energy chemistry (HEC)/hazardous chemistry. The study features an in-depth analysis, highlighting the capabilities of a diverse set of industry stakeholders.

One of the key objectives of this report was to estimate the existing market size and the future growth potential within the HEC/hazardous chemistry-based API manufacturing services market. Based on multiple parameters, such as the growth of the overall pharmaceutical drugs market, cost of goods sold, direct manufacturing costs and API manufacturing market, we have developed informed estimates on the financial evolution of the market, over the period 2020-2030.

The report also provides details on the likely distribution of the current and forecasted opportunity across:

In pharmaceutical manufacturing, the use of certain hazardous chemical reactions has been shown to enable developers to optimize existing production processes, as well as improve yields. In other words, certain chemical reactions, which are generally regarded as harmful, offer a more direct route to the end product, requiring fewer raw materials and involving a limited number of side reactions. As a result, the number of process steps are essentially reduced, when compared to using conventional synthesis chemistries.

Prominent examples of hazardous chemical reactions include nitrations, oxidations, hydrogenations, alkylations, and reactions involving unstable or highly active compounds (such as azides, nitrate esters, peroxides, diazo compounds and highly potent substances). Generally, such reactions are carried out under specialized temperature and pressure conditions. However, they are usually not considered during the early drug development stages, owing to the associated risks.

From a large-scale manufacturing perspective, the use of such techniques has been proven to offer substantial time and cost-related benefits. In this context, it is also worth mentioning that using hazardous synthesis chemistries it is possible to design new chemical structures, which have interesting bio-active properties, and offer the means to improve overall product quality.

Given the inherent risks associated with hazardous chemistry-based manufacturing processes, innovator companies (especially in the fine chemicals and pharmaceutical industries) prefer to outsource such processes to contract service providers. Presently, there are a number of contract chemicals manufacturers that claim to have the necessary capabilities and infrastructure to support the synthesis of APIs under hazardous conditions.

It is worth highlighting that such reactions are best contained within continuous flow processes. However, owing to various reasons (such as reaction specific complexities, fluctuating volumes and certain application-specific requirements) the fine chemicals and pharmaceutical industries tend to rely on the traditional batch process. However, there is an evident shift in operating preferences to continuous systems, which is anticipated to bring about revolutionary changes in the long term.

Considering the growing global population and the rising demand for new and effective drugs, faster and more efficient pharmaceutical manufacturing processes have become a necessity. In fact, if a drug against COVID-19 is successfully developed, it is imperative to develop high-efficiency processes to ensure the production of sufficient volumes of the therapeutic to treat the global population.

We are led to believe that the use of high energy chemistry and hazardous chemistries have much to offer in the aforementioned context. As a consequence, the contract services market catering to this segment of the pharmaceutical industry is anticipated to witness substantial growth in the coming years.

Amongst other elements, the report features:

In order to account for future uncertainties and to add robustness to our forecast model, we have provided three scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry's growth.

The opinions and insights presented in this study were also influenced by discussions conducted with stakeholders in this domain. All actual figures have been sourced and analyzed from publicly available information forums. Financial figures mentioned in this report are in USD, unless otherwise specified.

Key Topics Covered

1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION
3.1. Chapter Overview
3.2. Overview of High Energy Chemistry (HEC)/Hazardous Chemistry for Small Molecule API Manufacturing
3.3. Low Temperature/Cryogenic Chemistry
3.3.1. Reaction Conditions
3.3.2. Advantages
3.3.3. Affiliated Production Processes
3.3.4. Other Specific Requirements/Equipment
3.4. High Temperature Chemistry
3.5. High Pressure Chemistry
3.6. Low Pressure Chemistry
3.7. Need for HEC/Hazardous Chemistry for Small Molecule Manufacturing
3.7.1. Development of New and Complex Molecular Structures
3.7.2. Low Cost Generic API Synthesis
3.7.3. Route Scouting for Novel, Complex Molecules
3.8. Shift Towards Continuous Flow Chemistry

4. CASE STUDY: COMPARISON OF SMALL MOLECULES AND LARGE MOLECULES
4.1. Chapter Overview
4.2. Small Molecule and Large Molecule Drugs/Therapies
4.2.1. Comparison of Key Characteristics
4.2.2. Comparison of Manufacturing Processes
4.2.3. Comparison of Key Manufacturing-related Challenges

5. CURRENT MARKET LANDSCAPE
5.1. Chapter Overview
5.2. API Manufacturers with HEC Capability: Overall Market Landscape
5.2.1. Analysis by Type of Manufacturing Service
5.2.2. Analysis by Year of Establishment
5.2.3. Analysis by Company Size
5.2.4. Analysis by Geographical Location
5.2.5. Analysis by Location of Manufacturing Facilities
5.2.6. Analysis by General Pharmaceutical Manufacturing Portfolio
5.2.6.1. Analysis by Type of Product (API and FDF)
5.2.6.2. Analysis by HPAPI Manufacturing Capability
5.2.7. Analysis by Type of HEC Services Offered
5.2.7.1. Analysis by Temperature Conditions Handled
5.2.7.2. Analysis by Pressure Conditions Handled
5.2.8. Analysis by Availability of Continuous Flow Technology

6. REGIONAL CAPABILITY ASSESSMENT
6.1. Chapter Overview
6.2. List of Manufacturing Facilities having HEC Capabilities
6.2.1. Manufacturing Facilities in North America
6.2.1.1. Geographical Map Representation: Manufacturing Facilities with HEC Capabilities in North America
6.2.1.2. Analysis by Type of Reaction Conditions Handled
6.2.1.3. Analysis by Range of Reaction Conditions Handled
6.2.1.3.1. Analysis by Temperature Conditions Handled
6.2.1.3.2. Analysis by Pressure Conditions Handled
6.2.2. Manufacturing Facilities in Europe
6.2.3. Manufacturing Facilities in Asia-Pacific
6.3. Regional Capability Assessment Summary

7. COMPANY COMPETITIVENESS ANALYSIS
7.1. Chapter Overview
7.2. Key Parameters
7.3. Methodology
7.4. Competitiveness Analysis: Companies in North America
7.4.1. Companies in North America Offering HEC-based Contract Manufacturing
7.4.2. Companies in North America Offering HEC-based Custom Manufacturing
7.5. Competitiveness Analysis: Companies in Europe
7.6. Competitiveness Analysis: Companies in Asia-Pacific
7.7. Spider Web Analysis

8. COMPANY PROFILES
8.1. Chapter Overview
8.2. AGC Chemicals
8.2.1. Company Overview
8.2.2. Financial Information
8.2.3. Manufacturing Facility Details
8.2.4. HEC Specific Service Offerings
8.2.5. Recent Developments and Future Outlook
8.3. Beijing Mediking Biopharm
8.4. Cambrex
8.5. Corden Pharma
8.6. Evonik
8.7. Hovione
8.8. Patheon
8.9. PCI Synthesis
8.10. Siegfried

9. CASE STUDY I: SYNTHESIS REACTION PORTFOLIO OF COMPANIES
9.1. Context and Background
9.2. Reaction Portfolios of API Manufacturers with HEC Capabilities
9.2.1. Analysis by Most Popular Reactions
9.2.1.1. Most Popular Reactions: Portfolio of Large Players
9.2.1.2. Most Popular Reactions: Portfolio of Mid-sized Players
9.2.1.3. Most Popular Reactions: Portfolio of Small Players
9.2.1.4. Most Popular Reactions: Portfolio of Other Players
9.2.2. Analysis by Moderately Popular Reactions
9.2.3. Analysis by Less Popular Reactions
9.2.4 Analysis by Least Popular Reactions

10. CASE STUDY II: INNOVATION MAPPING IN HEC MARKET
10.1. Context and Background
10.2. HEC-based Contract Research and Custom Synthesis Service Providers: Overall Market Landscape
10.2.1. Analysis by Year of Establishment
10.2.2. Analysis by Company Size
10.2.3. Analysis by Geographical Location
10.2.4. Analysis by HEC Conditions Handled
10.2.5. Analysis by Availability of Continuous Flow Technology
10.2.6. Company Competitiveness Analysis

11. MARKET FORECAST
11.1. Chapter Overview
11.2. Forecast Methodology and Key Assumptions
11.3. Global HEC-based API Manufacturing Services Market, 2020-2030
11.4. HEC-based API Manufacturing Services Market: Distribution by Region, 2020-2030
11.4.1. HEC-based API Manufacturing Services Market in North America
11.4.2. HEC-based API Manufacturing Services Market in Europe
11.4.3. HEC-based API Manufacturing Services Market in Asia Pacific
11.5. HEC-based API Manufacturing Services Market: Distribution by Reaction Conditions, 2020-2030
11.6. HEC-Based API Manufacturing Services Market: Distribution by Scale of Operation, 2020-2030
11.7. Global HEC-Based API Manufacturing Services Market: Distribution by Company Size, 2020-2030

12. SWOT ANALYSIS
12.1 Chapter Overview
12.2. SWOT Analysis
12.3. Strengths
12.4. Weaknesses
12.5. Opportunities
12.6. Threats
12.7. Concluding Remarks

13. EXECUTIVE INSIGHTS

14. COVID-19 IMPACT
14.1. Chapter Overview
14.2. Evaluation of Impact of COVID-19 Outbreak
14.2.1. Current Initiatives and Recuperative Initiatives of Key Players
14.2.2. Impact on the future opportunity for HEC/Hazardous Chemistry-based API Manufacturing Services Market
14.3. Recuperative Strategies: Author's Perspective
14.3.1. Propositions for Immediate Implementation
14.3.2. Short/Long Term Steps

15. CONCLUSION

Companies Mentioned

For more information about this report visit https://www.researchandmarkets.com/r/n0bclq

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

CONTACT: ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900